Mallinckrodt plc to Report Earnings Results for First Quarter 2025
Mallinckrodt (MNK) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:30 a.m. ET on the same day.
Investors can participate through multiple channels, including a live call registration system, an audio-only webcast, or through the company's Investor Relations webpage.
Mallinckrodt (MNK) ha annunciato che rilascerà i suoi risultati finanziari del primo trimestre 2025 martedì 6 maggio 2025. La compagnia farmaceutica globale specializzata ospiterà una conferenza telefonica per gli investitori alle 8:30 a.m. ET lo stesso giorno.
Gli investitori possono partecipare attraverso diversi canali, inclusi un sistema di registrazione per la chiamata dal vivo, un webcast audio-only o tramite la pagina web delle Relazioni con gli Investitori della compagnia.
Mallinckrodt (MNK) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el martes 6 de mayo de 2025. La compañía farmacéutica global especializada llevará a cabo una conferencia telefónica para inversores a las 8:30 a.m. ET el mismo día.
Los inversores pueden participar a través de múltiples canales, incluyendo un sistema de registro para la llamada en vivo, un webcast solo de audio, o a través de la página web de Relaciones con Inversores de la compañía.
말린크로트 (MNK)는 2025년 1분기 재무 결과를 2025년 5월 6일 화요일에 발표할 것이라고 발표했습니다. 이 글로벌 전문 제약 회사는 같은 날 오전 8시 30분 ET에 투자자 회의 전화를 주최할 예정입니다.
투자자들은 라이브 전화 등록 시스템, 오디오 전용 웹캐스트 또는 회사의 투자자 관계 웹페이지를 통해 여러 경로로 참여할 수 있습니다.
Mallinckrodt (MNK) a annoncé qu'il publiera ses résultats financiers du premier trimestre 2025 le mardi 6 mai 2025. La société pharmaceutique spécialisée mondiale organisera une conférence téléphonique pour les investisseurs à 8h30 ET le même jour.
Les investisseurs peuvent participer par plusieurs canaux, y compris un système d'enregistrement pour l'appel en direct, un webinaire audio uniquement, ou via la page des Relations avec les Investisseurs de l'entreprise.
Mallinckrodt (MNK) hat angekündigt, dass es seine Finanzergebnisse für das erste Quartal 2025 am Dienstag, den 6. Mai 2025, veröffentlichen wird. Das globale Spezialpharmaunternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz für Investoren veranstalten.
Investoren können über mehrere Kanäle teilnehmen, darunter ein Live-Anrufregistrierungssystem, ein Audio-Only-Webcast oder über die Webseite für Investor Relations des Unternehmens.
- None.
- None.
A conference call for investors will begin at 8:30 a.m. ET and can be accessed as follows:
- Live Call Participant Registration (including dial-in): https://register-conf.media-server.com/register/BI59a8cb021a314d8683b4822df03f9735
- Audio-Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/tkagfrhx
- On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the
Investor Relations Contact
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-first-quarter-2025-302424998.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) release Q1 2025 earnings?
What time is Mallinckrodt's (MNK) Q1 2025 earnings call?
How can investors access Mallinckrodt's (MNK) Q1 2025 earnings call?
Where can I find the webcast link for Mallinckrodt's (MNK) Q1 2025 earnings?
